The influence of OLR1 and PCSK9 gene polymorphisms on ischemic stroke: Evidence from a meta-analysis

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Au, Anthony ^a   Griffiths, Lyn R ^b   Cheng, Kian Kai ^a   Wee Kooi, Cheah ^c   Irene, Looi ^d   Keat Wei, Loo ^e  

^a UNIVERSITI TEKNOLOGI MALAYSIA   (Malaysia)

^b QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^c Taiping Hospital   (Malaysia)

^d Hospital Seberang Jaya   (Malaysia)

^e UNIVERSITI TUNKU ABDUL RAHMAN   (Malaysia)

Author keywords

[No Author keywords available]

Indexed keywords

OLR1 PROTEIN, HUMAN; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR 1; PCSK9 PROTEIN, HUMAN; PROPROTEIN CONVERTASE 9; SERINE PROTEINASE;

ALLELE; CEREBROVASCULAR ACCIDENT; GENETIC ASSOCIATION STUDY; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; HUMAN; META ANALYSIS; ODDS RATIO; PUBLISHING; SINGLE NUCLEOTIDE POLYMORPHISM;

ALLELES; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; PROPROTEIN CONVERTASE 9; PROPROTEIN CONVERTASES; PUBLICATION BIAS; SCAVENGER RECEPTORS, CLASS E; SERINE ENDOPEPTIDASES; STROKE;

EID: 84950157591     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep18224     Document Type: Article

References (39)

1. Loo, K. W. and Gan, S. H. Burden of stroke in Malaysia. Int. J. Stroke 7, 165-167 (2012).
2. Wei, L. K., Au, A., Menon, S., Gan, S. H. and Griffiths, L. R. Clinical Relevance of MTHFR, eNOS, ACE, and ApoE Gene Polymorphisms and Serum Vitamin Profile among Malay Patients with Ischemic Stroke. J. Stroke Cerebrovasc. Dis 24, 2017-2025 (2015).
3. Sawamura, T., Wakabayashi, I. and Okamura, T. LOX-1 in atherosclerotic disease. Clin. Chim. Acta 440, 157-163 (2015).
4. Zhang, L. et al. Proprotein convertase subtilisin/kexin type 9 (PCSK9) in lipid metabolism, atherosclerosis and ischemic stroke. Int. J. Neurosci. (2015). doi :10.3109/00207454.2015.1057636.
5. Yoshimoto, R. et al. The discovery of LOX-1, its ligands and clinical significance. Cardiovasc. Drugs Ther. 25, 379-391 (2011).
6. Pirillo, A., Norata, G. D. and Catapano, A. L. LOX-1, OxLDL, and atherosclerosis. Mediators Inflamm. (2013). doi: 10.1155/2013/152786.
7. Biocca, S. et al. Functional analysis and molecular dynamics simulation of LOX-1 K167N polymorphism reveal alteration of receptor activity. PLoS ONE 4, e4648 (2009).
8. Tatsuguchi, M. et al. Oxidized LDL receptor gene (OLR1) is associated with the risk of myocardial infarction. Biochem. Biophys. Res. Commun. 303, 247-250 (2003).
9. Hou, X. W. et al. The G501C polymorphism of oxidized LDL receptor gene [OLR-1] is associated with susceptibility and serum C-reactive protein concentration in Chinese essential hypertensives. Clin. Chim. Acta 388, 200-203 (2008).
10. Wang, L. et al. A candidate gene study revealed sex-specific association between the OLR1 gene and carotid plaque. Stroke 42, 588-592 (2011).
11. Hattori, H. et al. G501C polymorphism of oxidized LDL receptor gene (OLR1) and ischemic stroke. Brain Res. 1121, 246-249 (2006).
12. Li, D. S. The study on the association between the LOX1-501G→ C polymorphism and stroke. Masters thesis, Central South University. (2009). Available at: http://122.207.86.53/xwlw/detail.jsp?record= 633&back613&channelid= 65382 (Accessed: 20th June 2015
13. Zhang, J. et al. The role of OLR1 polymorphisms in determining the risk and prognosis of ischemic stroke in a Chinese population. NeuroRehabilitation 32, 391-396 (2013).
14. Liu, X., Zhu, R. X., Li, L. and He, Z. Y. Association of LOX-1 gene polymorphisms with cerebral infarction in northern Chinese Han population. Lipids Health Dis. 13, 55 (2014).
15. Seidah, N. G. The proprotein convertases, 20 years later. Methods Mol. Biol. 768, 23-57 (2011).
16. Lagace, T. A. et al. Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice. J. Clin. Invest. 116, 2995-3005 (2006).
17. Rousselet, E. et al. PCSK9 reduces the protein levels of the LDL receptor in mouse brain during development and after ischemic stroke. J. Lipid Res. 52, 1383-1391 (2011).
18. Aung, L. H. et al. The proprotein convertase subtilisin/kexin type 9 gene E670G polymorphism and serum lipid levels in the Guangxi Bai Ku Yao and Han populations. Lipids Health Dis. 10, 5 (2011).
19. Abboud, S. et al. Proprotein convertase subtilisin/kexin type 9 (PCSK9) gene is a risk factor of large-vessel atherosclerosis stroke. PLoS ONE. 2, e1043 (2007).
20. Zhang, D. W. et al. Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation. J. Biol. Chem. 282, 18602-18612 (2007).
21. Slimani, A. et al. Effect of E670G Polymorphism in PCSK9 Gene on the Risk and Severity of Coronary Heart Disease and Ischemic Stroke in a Tunisian Cohort. J. Mol. Neurosci. 53, 150-157 (2014).
22. Han, D. et al. Correlation of PCSK9 gene polymorphism with cerebral ischemic stroke in Xinjiang Han and Uygur populations. Med. Sci. Monit. 20, 1758-1767 (2014).
23. Ding, Z. et al. Cross-talk between LOX-1 and PCSK9 in vascular tissues. Cardiovascular Research 107, 556-567 (2015).
24. Inoue, N. et al. LOX index, a novel predictive biochemical marker for coronary heart disease and stroke. Clin. Chem. 56, 550-558 (2010).
25. Wang, L. et al. A candidate gene study revealed sex-specific association between the OLR1 gene and carotid plaque. Stroke 42, 588-592 (2011).
26. Predazzi, I. et al. Association between OLR1 K167N SNP and intima media thickness of the common carotid artery in the general population. PLoS ONE 7, e31086 (2012).
27. Xu, X. et al. The Gene Polymorphism of LOX1 Predicts the Incidence of LVH in Patients with Essential Hypertension. Cellular Physiology and Biochemistry 33, 88-96 (2014).
28. Brinkley, T. E. et al. Variation in the human lectin-like oxidized low-density lipoprotein receptor 1 (LOX-1) gene is associated with plasma soluble LOX-1 levels. Exp. Physiol. 93, 1085-1090 (2008).
29. Raal, F. J. et al. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. Lancet 385, 341-350 (2015).
30. Raal, F. J. et al. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet 385, 331-340 (2015).
31. Blom, D. J. et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N. Engl. J. Med. 370, 1809-1819 (2014).
32. Chen, S. N. et al. A common PCSK9 haplotype, encompassing the E670G coding single nucleotide polymorphism, is a novel genetic marker for plasma low-density lipoprotein cholesterol levels and severity of coronary atherosclerosis. J. Am. Coll. Cardiol. 45, 1611-1619 (2005).
33. Evans, D. and Beil, F. U. The E670G SNP in the PCSK9 gene is associated with polygenic hypercholesterolemia in men but not in women. BMC Med. Genet. 7, 66 (2006).
34. Norata, G. D. et al. Effects of PCSK9 variants on common carotid artery intima media thickness and relation to ApoE alleles. Atherosclerosis. 208, 177-182 (2010).
35. Hsu, L. A. et al. The PCSK9 gene E670G polymorphism affects low-density lipoprotein cholesterol levels but is not a risk factor for coronary artery disease in ethnic Chinese in Taiwan. Clin. Chem. Lab. Med. 47, 154-158 (2009).
36. Scartezini, M. et al. The PCSK9 gene R46L variant is associated with lower plasma lipid levels and cardiovascular risk in healthy U.K. men. Clin. Sci. 113, 435-441 (2007).
37. Polisecki, E. et al. Genetic variation at the PCSK9 locus moderately lowers low-density lipoprotein cholesterol levels, but does not significantly lower vascular disease risk in an elderly population. Atherosclerosis. 200, 95-101 (2008).
38. Huang, C. C. et al. Longitudinal association of PCSK9 sequence variations with low-density lipoprotein cholesterol levels: the Coronary Artery Risk Development in Young Adults Study. Circ. Cardiovasc. Genet. 2, 354-361 (2009).
39. Viechtbauer, W. Conducting Meta-Analyses in R with the metafor Package. J Stat. Softw. 36, 1-48 (2010).